Speakers: Daniel Murphy, DC, DABCO and Steven Shanks, President of Erchonia Corporation
Register for this webinar to learn:
➔ Integrate concepts in laser phototherapy: wavelength, frequency, speed of light, fluence, penetration, secondary and primary physiological influences.
➔ Compare the differences between thermal and non-thermal laser therapy.
➔ Develop the relationship between mitochondria, free radicals, ATP, cytochrome c oxidase enzyme and laser photon therapy.
➔ Discuss the physiology of applying laser therapy to both the anatomical part of the injury/complaint and the nerve roots that innervate that anatomical part.
➔ Explain the biphasic nature of laser phototherapy in relation to evolutionary biology and current clinical applications.
About the speakers:
Daniel Murphy, DC, DABCO is a recognized, award-winning chiropractor and popular instructor who teaches internationally while maintaining a part-time clinical practice. He has taught over 1,610 twelve-hour postgraduate continuing education courses. He is also a part-time undergraduate professor at Life Chiropractic College West, where he currently teaches seniors on the management of spinal disorders. He has taught graduate courses for a long list of chiropractic colleges and individual programs. He is the author of several books and a quarterly columnist in the American Journal of Clinical Chiropractic. From 2003 to 2009, Daniel Murphy, DC, DABCO served as Vice President of the International Chiropractic Association. In 2014, he received the Lifetime Achievement Award from the International Association of Functional Neurology and Rehabilitation (IAFNR).
Steven Shanks, President of Erchonia Corporation; is at the forefront of medical innovation and the growth of low-level laser technology. He has spent the past 20 years championing and promoting bio-modulation as an alternative modality to invasive procedures and primary treatment. A calculated risk-taker, with a deep understanding of clinical research, he has dedicated his knowledge to finding applications that advance safe, effective and non-invasive medical technology. Even with numerous FDA-issued market clearances under his belt, all granted based on FDA IRB-approved Tier 1 clinical trials and the creation of a new product code OLI, Steven Shanks continues to research opportunities where low-level laser as a medical drug This modality can improve health care and quality of life.